LIDERA BC
What it tests: Giredestrant in ER+ HER2− early breast cancer: efficacy/safety by menopausal status (phase III)
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.